Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy
Open Access
- 20 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death Discovery
- Vol. 6 (1), 1-12
- https://doi.org/10.1038/s41420-020-0237-8
Abstract
RB1 loss (RB1null) or MYCN amplification (MYCNamp) in fetal human retina causes retinoblastoma. SKP2 loss kills RB1null cells, but small molecule SKP2 inhibitors remain unexplored therapeutically. Whether SKP2 is synthetic lethal in MYCNamp retinoblastoma is unclear. SKP2 is the substrate recognition component of two Cullin-RING Ligase complexes (CRL1SKP2/SCFSKP2, and CRL4SKP2), a family of multiprotein E3 ubiquitin ligases. NEDD8 activating enzyme (NAE) is required for Cullin neddylation and thus CRL activation. Here, we show that the NAE inhibitor, Pevonedistat (MLN4924), potently inhibits RB1null and MYCNamp tumors. Intravitreal MLN4924 suppressed multiple human xenografts with EC80s from 20 ng to 3.5 μg. Maximum tolerated dose (MTD) was 10–30 μg, highlighting a favorable therapeutic window. Inhibition of Cullin neddylation was similar in all cases, but cellular effects ranged from G1 arrest with apoptosis to G2/M arrest with endoreplication. However, even in less sensitive lines (EC50 ≈ 1 μM), prolonged exposure was lethal or induced persistent cytostasis. Mechanistically, depleting any single Cullin did not fully recapitulate drug phenotypes, but sensitivity to SKP2 loss correlated with that of drug. Thus, intravitreal MLN4924 is a promising new retinoblastoma therapy, mimicking the cancer-specific lethality of eliminating SKP2 complexes.Keywords
Funding Information
- Gouvernement du Canada | Canadian Institutes of Health Research (153128)
- Krembil Foundation (NA)
- Cancer Research Society (NA)
This publication has 45 references indexed in Scilit:
- RetinoblastomaNature Reviews Disease Primers, 2015
- The Classification of Vitreous Seeds in Retinoblastoma and Response to Intravitreal MelphalanOphthalmology, 2015
- Cullin Family Proteins and Tumorigenesis: Genetic Association and Molecular MechanismsJournal of Cancer, 2015
- SCF ubiquitin ligase-targeted therapiesNature Reviews Drug Discovery, 2014
- Intravitreal Melphalan for Persistent or Recurrent Retinoblastoma Vitreous SeedsJAMA Ophthalmology, 2014
- Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studiesThe Lancet Oncology, 2013
- Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indicationsBritish Journal of Ophthalmology, 2012
- One hit, two hits, three hits, more? Genomic changes in the development of retinoblastomaGenes, Chromosomes and Cancer, 2007
- Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box proteinProceedings of the National Academy of Sciences of the United States of America, 1998
- Human CUL-1, but not other cullin family members, selectively interacts with SKP1 to form a complex with SKP2 and cyclin A.1998